Vertex Pharmaceuticals Incorporated
VRTX
$477.89
$3.620.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.19B | 3.08B | 2.94B | 2.76B | 2.91B |
| Total Other Revenue | 0.00 | -- | 20.70M | 10.00M | -- |
| Total Revenue | 3.19B | 3.08B | 2.96B | 2.77B | 2.91B |
| Cost of Revenue | 1.44B | 1.39B | 1.39B | 1.34B | 1.42B |
| Gross Profit | 1.75B | 1.68B | 1.58B | 1.43B | 1.49B |
| SG&A Expenses | 487.00M | 445.10M | 424.60M | 396.40M | 377.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.93B | 1.84B | 1.81B | 1.74B | 1.80B |
| Operating Income | 1.26B | 1.24B | 1.15B | 1.03B | 1.11B |
| Income Before Tax | 1.33B | 1.30B | 1.28B | 730.40M | 1.14B |
| Income Tax Expenses | 139.90M | 215.90M | 250.10M | 84.10M | 223.50M |
| Earnings from Continuing Operations | 1.19B | 1.08B | 1.03B | 646.30M | 913.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.19B | 1.08B | 1.03B | 646.30M | 913.00M |
| EBIT | 1.26B | 1.24B | 1.15B | 1.03B | 1.11B |
| EBITDA | 1.29B | 1.29B | 1.21B | 1.08B | 1.13B |
| EPS Basic | 4.69 | 4.24 | 4.02 | 2.52 | 3.55 |
| Normalized Basic EPS | 3.40 | 3.31 | 3.12 | 2.79 | 2.96 |
| EPS Diluted | 4.65 | 4.20 | 3.99 | 2.49 | 3.50 |
| Normalized Diluted EPS | 3.37 | 3.28 | 3.09 | 2.76 | 2.93 |
| Average Basic Shares Outstanding | 253.90M | 255.60M | 256.70M | 256.90M | 257.50M |
| Average Diluted Shares Outstanding | 256.10M | 257.60M | 258.90M | 259.50M | 260.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |